Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

NCT04295863 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT04295863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04295863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Recruiting
Start date
June 25, 2020
Completion date
April 12, 2026
Enrollment
264 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer